Cargando…

Combination of tyrosine kinase inhibitors and the MCL1 inhibitor S63845 exerts synergistic antitumorigenic effects on CML cells

Tyrosine kinase inhibitor (TKI) treatment has dramatically improved the survival of chronic myeloid leukemia (CML) patients, but measurable residual disease typically persists. To more effectively eradicate leukemia cells, simultaneous targeting of BCR-ABL1 and additional CML-related survival protei...

Descripción completa

Detalles Bibliográficos
Autores principales:	Malyukova, Alena, Ujvari, Dorina, Yektaei-Karin, Elham, Zovko, Ana, Madapura, Harsha S., Keszei, Marton, Nagy, Noemi, Lotfi, Kourosh, Björn, Niclas, Wallvik, Jonas, Tamai, Minori, Nguyen, Thao T. T., Akahane, Koshi, Inukai, Takeshi, Stenke, Leif, Salamon, Daniel
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8464601/ https://www.ncbi.nlm.nih.gov/pubmed/34564697 http://dx.doi.org/10.1038/s41419-021-04154-0

Ejemplares similares

IFNγ directly counteracts imatinib-induced apoptosis of primary human CD34+ CML stem/progenitor cells potentially through the upregulation of multiple key survival factors
por: Ujvari, Dorina, et al.
Publicado: (2022)

MCL-1 Inhibitor S63845 Distinctively Affects Intramedullary and Extramedullary Hematopoiesis
por: Zhang, Hexiao, et al.
Publicado: (2023)

BMI1-Inhibitor PTC596 in Combination with MCL1 Inhibitor S63845 or MEK Inhibitor Trametinib in the Treatment of Acute Leukemia
por: Seipel, Katja, et al.
Publicado: (2021)

MCL1 inhibitors S63845/MIK665 plus Navitoclax synergistically kill difficult-to-treat melanoma cells
por: Mukherjee, Nabanita, et al.
Publicado: (2020)

Sensitivity of Cutaneous T-Cell Lymphoma Cells to the Mcl-1 Inhibitor S63845 Correlates with the Lack of Bcl-w Expression
por: Sumarni, Uly, et al.
Publicado: (2022)

Pharmaceutical Drug Metformin and MCL1 Inhibitor S63845 Exhibit Anticancer Activity in Myeloid Leukemia Cells via Redox Remodeling
por: Valiulienė, Giedrė, et al.
Publicado: (2021)

Constitutive BAK/MCL1 complexes predict paclitaxel and S63845 sensitivity of ovarian cancer
por: Liu, Dongyan, et al.
Publicado: (2021)

The MCL1-specific inhibitor S63845 acts synergistically with venetoclax/ABT-199 to induce apoptosis in T-cell acute lymphoblastic leukemia cells
por: Li, Zhaodong, et al.
Publicado: (2018)

Dual intracellular targeting by ruxolitinib and the Mcl-1 inhibitor S63845 in interleukin-6-dependent myeloma cells blocks in vivo tumor growth
por: Burger, Renate, et al.
Publicado: (2021)

Correction: Constitutive BAK/MCL1 complexes predict paclitaxel and S63845 sensitivity of ovarian cancer
por: Liu, Dongyan, et al.
Publicado: (2021)

Rationale for a Combination Therapy with the STAT5 Inhibitor AC-4-130 and the MCL1 Inhibitor S63845 in the Treatment of FLT3-Mutated or TET2-Mutated Acute Myeloid Leukemia
por: Seipel, Katja, et al.
Publicado: (2021)

Myeloid Cell Leukemia 1 Small Molecule Inhibitor S63845 Synergizes with Cisplatin in Triple-Negative Breast Cancer
por: Acton, Alexus, et al.
Publicado: (2023)

PPARα Ligands as Antitumorigenic and Antiangiogenic Agents
por: Pozzi, Ambra, et al.
Publicado: (2008)

Antitumorigenic Effect of Hsp90 Inhibitor SNX-2112 on Tongue Squamous Cell Carcinoma is Enhanced by Low-Intensity Ultrasound
por: Nan, Chuanchuan, et al.
Publicado: (2020)

Kinase Inhibitor Therapy in CML: It's What's Inside That Counts
por: Eide, Christopher A., et al.
Publicado: (2013)

Ponatinib and other CML Tyrosine Kinase Inhibitors in Thrombosis
por: Zeng, Peng, et al.
Publicado: (2020)

Axitinib Has Antiangiogenic and Antitumorigenic Activity in Myxoid Liposarcoma
por: Kerr, Lauren T., et al.
Publicado: (2016)

The MCL-1 BH3 Helix is an Exclusive MCL-1 inhibitor and Apoptosis Sensitizer
por: Stewart, Michelle L., et al.
Publicado: (2010)

Bcr-Abl Tyrosine Kinase Inhibitors in the Treatment of Pediatric CML
por: Carofiglio, Francesca, et al.
Publicado: (2020)

IMiDs uniquely synergize with TKIs to upregulate apoptosis of Philadelphia chromosome-positive acute lymphoblastic leukemia cells expressing a dominant-negative IKZF1 isoform
por: Harama, Daisuke, et al.
Publicado: (2021)

Antitumorigenic effect of interferon-β by inhibition of undifferentiated glioblastoma cells
por: YAMAMURO, SHUN, et al.
Publicado: (2015)

Abstract 105: Deferoxamine: A Regenerative Therapeutic with Antitumorigenic Potential
por: Donneys, Alexis, et al.
Publicado: (2018)

T315I mutation of BCR-ABL1 into human Philadelphia chromosome-positive leukemia cell lines by homologous recombination using the CRISPR/Cas9 system
por: Tamai, Minori, et al.
Publicado: (2018)

Varying effects of tyrosine kinase inhibitors on platelet function—A need for individualized CML treatment to minimize the risk for hemostatic and thrombotic complications?
por: Deb, Suryyani, et al.
Publicado: (2019)

Immunological monitoring of newly diagnosed CML patients treated with bosutinib or imatinib first-line
por: Kreutzman, Anna, et al.
Publicado: (2019)

Stroma-Mediated Resistance to S63845 and Venetoclax through MCL-1 and BCL-2 Expression Changes Induced by miR-193b-3p and miR-21-5p Dysregulation in Multiple Myeloma
por: Algarín, Esperanza M., et al.
Publicado: (2021)

Decoding the mechanism behind MCL-1 inhibitors: A pathway to understanding MCL-1 protein stability
por: Tantawy, Shady I., et al.
Publicado: (2023)

Eosinophils Exert Antitumorigenic Effects in the Development of Esophageal Squamous Cell Carcinoma
por: Jacobse, Justin, et al.
Publicado: (2023)

Association of relapse-linked ARID5B single nucleotide polymorphisms with drug resistance in B-cell precursor acute lymphoblastic leukemia cell lines
por: Tamai, Minori, et al.
Publicado: (2020)

Utility of ASNS gene methylation evaluated with the HPLC method as a pharmacogenomic biomarker to predict asparaginase sensitivity in BCP-ALL
por: Watanabe, Atsushi, et al.
Publicado: (2023)

Intracellular Retention of ABL Kinase Inhibitors Determines Commitment to Apoptosis in CML Cells
por: Lipka, Daniel B., et al.
Publicado: (2012)

Creation of Philadelphia chromosome by CRISPR/Cas9-mediated double cleavages on BCR and ABL1 genes as a model for initial event in leukemogenesis
por: Tamai, Minori, et al.
Publicado: (2022)

Antitumorigenic Evaluation of Thalidomide Alone and in Combination with Cisplatin in DBA2/J Mice
por: Ruddy, Jean Marie B., et al.
Publicado: (2002)

The Antitumorigenic Function of EGFR in Metastatic Breast Cancer is Regulated by Expression of Mig6
por: Wendt, Michael K., et al.
Publicado: (2015)

An antitumorigenic role for the IL-33 receptor, ST2L, in colon cancer
por: O'Donnell, Charlotte, et al.
Publicado: (2016)

Abstract: Antitumorigenic Effect of Deferoxamine on Human Head and Neck Cancer Cell Proliferation
por: Donneys, Alexis, et al.
Publicado: (2018)

Neuronal Nitric Oxide Synthase Induction in the Antitumorigenic and Neurotoxic Effects of 2-Methoxyestradiol
por: Gorska, Magdalena, et al.
Publicado: (2014)

Antitumorigenic and antiangiogenic efficacy of apatinib in liver cancer evaluated by multimodality molecular imaging
por: Liang, Qian, et al.
Publicado: (2019)

Antitumorigenic Effect of Tramadol and Synergistic Effect With Doxorubicin in Human Breast Cancer Cells
por: Huang, Yi-Hsuan, et al.
Publicado: (2022)

Purported Mcl-1 inhibitor marinopyrrole A fails to show selective cytotoxicity for Mcl-1-dependent cell lines
por: Eichhorn, J M, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_cs8bd4s7ugr4n7dl1inbdqracq